CW November 2002
Volume 11Issue Number 11 November 2002 ISSN 10593802 Results of a Phase II Trial of Metastatic Breast Cancer PatientsA novel combination of vinorelbine and Herceptin is a promising first-line therapy for Her2-positive advanced breast cancer patients. It is well-tolerated and shows less cardiac toxicity compared to anthracycline-based combination therapy with Herceptin.
Go to Previous Page Go to Next Page Source & Additional Reading M. Jahanzeb et al., The Oncologist, October, 2002. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW November 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
